Privia Health Q2 revenue beats estimates, outlook raised
PRVA•Guidance raised for 2026
The U.S. physician enablement firm raised full-year 2026 guidance for all key financial metrics.
The company now sees 2026 revenue at $2.45 bln, the high end of its prior range, and expects adjusted EBITDA at $155 mln, the mid to high end of the range.
Quarterly results beat estimates
Privia Health said second-quarter revenue rose 21% year over year, beating analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $632.60 mln | $598.84 mln (17 Analysts) |
| Q2 EPS | $0.07 | ||
| Q2 Net Income | $9 mln | ||
| Q2 Operating Income | $11.80 mln |
Operating trends and analyst coverage
- Implemented providers grew 10% year over year, supporting revenue and operational gains.
- Attributed lives under value-based care arrangements increased 19% year over year.
- Practice collections rose 12% year over year, reflecting higher patient volumes and service delivery.
The current average analyst rating on the shares is "buy," with 18 "strong buy" or "buy" recommendations, 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Privia Health Group Inc is $31.00, about 29.4% above its August 5 closing price of $23.96. The stock recently traded at 70 times the next 12-month earnings versus a P/E of 61 three months ago.
